Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) EBT Margin (2016 - 2025)

Ligand Pharmaceuticals' EBT Margin history spans 16 years, with the latest figure at 95.16% for Q4 2025.

  • For Q4 2025, EBT Margin rose 18673.0% year-over-year to 95.16%; the TTM value through Dec 2025 reached 59.29%, up 5779.0%, while the annual FY2025 figure was 59.29%, 5779.0% up from the prior year.
  • EBT Margin for Q4 2025 was 95.16% at Ligand Pharmaceuticals, down from 122.24% in the prior quarter.
  • Across five years, EBT Margin topped out at 366.22% in Q1 2024 and bottomed at 157.45% in Q2 2024.
  • The 5-year median for EBT Margin is 22.21% (2022), against an average of 28.52%.
  • The largest annual shift saw EBT Margin surged 23994bps in 2024 before it crashed -47691bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 31.7% in 2021, then soared by 51bps to 47.91% in 2022, then rose by 27bps to 60.84% in 2023, then plummeted by -250bps to 91.56% in 2024, then skyrocketed by 204bps to 95.16% in 2025.
  • Per Business Quant, the three most recent readings for LGND's EBT Margin are 95.16% (Q4 2025), 122.24% (Q3 2025), and 23.56% (Q2 2025).